Episode 01
How Catalytic Capital Creates Women’s Health Markets
This episode is a must-listen for founders navigating the commercialization battlefield, investors allocating capital into women’s health, and operators building through the long middle before momentum is visible.
Episode 02
The 20 Year “Overnight Success” in Women’s Health Skip Baldino
In this episode of Blindspot Capital, Maryann sits down with Skip Baldino (former CEO of Gynesonics and current board member at Channel Medsystems) to unpack what it really takes to commercialize a women’s health medical technology inside a system built to resist change.
Episode 03
Why Doctors Still Miss the Signs of Women’s Heart Disease | Professor Angela Maas
In this episode of Blindspot Capital, Maryann speaks with Professor Angela Maas, cardiologist, clinician-scientist, and one of Europe’s earliest pioneers of sex-specific cardiovascular medicine, about why women’s heart disease has been misunderstood for decades—and what medicine still gets wrong today.
Episode 04
Heart Disease in Women | Hormones, Menopause, and Cardiovascular Risk | Carolin Lerchenmueller
In this episode of Blindspot Capital, Maryann speaks with Professor Carolin Lerchenmüller, cardiologist, clinician-scientist, and Switzerland’s first Chair of Gender Medicine, about why heart disease presents differently in women and how hormones across pregnancy, perimenopause, and menopause fundamentally reshape cardiovascular risk.
Episode 05
Tough Love for Women’s Health Founders: What VCs Really Think
In this episode, venture investor Lisa Suennen shares the unfiltered truths behind women’s health funding from why most founders lead with emotion instead of economics to what every pitch gets wrong about venture capital.
Episode 06
The Asset You Never Hear About
They call it the debasement trade — the quiet playbook the wealthy use when cash is losing value. In this episode, we decode how Wall Street hedges against inflationary decay, what most investors miss, and why the next decade of money won’t look like the last.
Episode 07
The Algorithms Are Silencing Women | Anna O’Sullivan on Censorship, Health & Digital Power
Over 95% of women's health brands report experiencing some form of suppression. Posts about menopause, fertility, libido, and endometriosis are being flagged as "sensitive" or "inappropriate" across major platforms even when the content is medically reviewed. This isn’t just a glitch. It’s a structural blind spot that affects funding, awareness, and access.
Episode 08
Why FemTech Was Just the Beginning | Ida Tin on Language, Power & Cultural Change
What if naming something was the first step to making it fundable? In 2016, Ida Tin didn’t just build one of the world’s most trusted women’s health apps, she gave the category a name. FemTech is now a global movement. But as she tells us in this powerful conversation, it started as a simple attempt to make investors listen.
Episode 09
Why Most Digital Health Startups Will Fail | Sergei Polevikov on AI Hype, VC Bias & Blindspots
Most digital health startups won’t survive. Not because the ideas are bad but because the system is broken.
This week, I’m joined by Sergei Polevikov , mathematician, investor, and co-host of Digital Health Inside Out for a no-fluff conversation on what’s really wrong with the digital health ecosystem.
Episode 07
The Algorithms Are Silencing Women | Anna O’Sullivan on Censorship, Health & Digital Power
Over 95% of women's health brands report experiencing some form of suppression. Posts about menopause, fertility, libido, and endometriosis are being flagged as "sensitive" or "inappropriate" across major platforms even when the content is medically reviewed. This isn’t just a glitch. It’s a structural blind spot that affects funding, awareness, and access.
Episode 08
Why FemTech Was Just the Beginning | Ida Tin on Language, Power & Cultural Change
What if naming something was the first step to making it fundable? In 2016, Ida Tin didn’t just build one of the world’s most trusted women’s health apps, she gave the category a name. FemTech is now a global movement. But as she tells us in this powerful conversation, it started as a simple attempt to make investors listen.
Episode 09
Why Most Digital Health Startups Will Fail | Sergei Polevikov on AI Hype, VC Bias & Blindspots
Most digital health startups won’t survive. Not because the ideas are bad but because the system is broken.
This week, I’m joined by Sergei Polevikov , mathematician, investor, and co-host of Digital Health Inside Out for a no-fluff conversation on what’s really wrong with the digital health ecosystem.
Episode 10
Women’s health innovation is no longer optional. In this episode, Sabrina Johnson, CEO of Daré Bioscience (NASDAQ: DARE), reveals what real science in women’s health looks like — from contraception and menopause to sexual health and biotech breakthroughs.
In this episode of Blindspot Capital, Maryann speaks with Professor Carolin Lerchenmüller, cardiologist, clinician-scientist,
Episode 11
Can We Finally Detect Preeclampsia Before It’s Too Late?
She explores why diagnostics haven’t evolved in nearly a century, what new science is finally emerging, and why investors are still ignoring one of the biggest opportunities in maternal health innovation.
Episode 12
The Billion Dollar Blindspot in Healthcare
Blindspot Capital is the podcast where health innovation meets investment insight. We talk to the founders building what should have existed. The investors backing what’s next. And the strategists reshaping the capital stack before it’s too late.
Episode 13
Women’s Heart Attacks Were Never Atypical
